Sensabues breath collection technology integrated into RCU Labs’ Test to determine recent cannabis use.
Stockholm, Sweden and Roseville, California, USA., March 6, 2020 — Sensabues AB (“Sensabues”), a leading provider of breath collection technology for detection of drugs, doping and diseases, today announced that it has partnered with RCU Labs, Inc. (“RCU Labs”), a leader in the development of a dual-matrix test for recent cannabis use.
The partnership will see Sensabues and RCU Labs combine their respective technologies to launch the first accurate Recent Cannabis Use Test (“RCU Test”) using breath collection. The new test solves one of the most scientifically elusive issues of the cannabis industry: how to determine whether an impaired driver or employee is under the influence of cannabis.
The RCU Test is the first reliable test method to accurately determine recent cannabis use within the impairment window. The RCU Test is a practical alternative to zero-tolerance and arbitrary tetrahydrocannabinol (THC) drug level policies.
RCU Labs has developed a new pharmacological testing approach based on multiple parameters involving key cannabinoids and Delta9-THC metabolites in blood. The results of the blood test are able to determine recent cannabis use within six hours. To enhance the confidence levels of the RCU Test, RCU Labs has incorporated a second test matrix, exhaled breath, utilizing the patented, low-cost breath collection device from Sensabues. The breath sample can be collected roadside or at an incident site, while the blood sample can be collected at the same time or, if required, up to several hours later. Both the breath and blood samples are then sent to the lab and analyzed using established instrumentation techniques such as high-resolution mass spectrometry for confirmatory data and evidential results. Overall, this dual-matrix approach yielded 100% accuracy within the impairment window following smoking in the first 44 consecutive subjects that have been studied in a clinical trial to date.
This collaboration seeks to advance the application breakthrough achieved by the RCU Test (patents pending) for law enforcement, workplace drug testing and anti-doping in sport with regard to ease of use and deployment in the field, as well as analytical accuracy in the lab. The RCU Test has obvious applications for law enforcement (roadside DUI collection), for employers investigating workplace incidents (with cause and post-accident situations) and for anti-doping in sport (in-competition testing of athletes and players).
Under this agreement, both parties will work to offer a full suite of approved RCU all-in-one and one-time-use test kits together with the validated RCU analytical lab services. Further joint development of RCU Labs’ method is planned to extend the offering to include a definitive recent-use test for other drug groups such as stimulants and performance enhancing drugs.
Notes to Editors
More about Sensabues’ exhaled breath method:
Exhaled breath contains aerosols which originate from lungs and blood. These aerosols contain revealing information for diagnostics, therapeutics and analytics. Sensabues owns the core IP for the design of a simple collection device and the validated methodology to collect, extract and detect the non-volatile substances present within these aerosols using electrostatic filter technology.
This technique is convenient, reliable and low cost. It is a non-invasive way to collect chemicals in breath for disease detection, exposure monitoring, and drug metabolism.
This is a highly sensitive, accurate and confirmatory, back-to-lab based technique, which has been developed into a complete end-to-end analytical platform for use in toxicology, pharmacology and clinical biochemistry that can lead to improved analysis, diagnostics and therapies for medical research, healthcare, law enforcement, criminal justice, schools, workplace drug testing and sports organizations.
About Sensabues AB:
Sensabues is a Swedish company with exclusive ownership of a novel method and device to detect non-volatiles in breath. Over 20,000 breath collection devices have been deployed across targeted applications/markets worldwide. There are over 35 technical papers published with data from multiple worldwide studies and large scale field trials by independent third-party labs, institutes, hospitals, clinics, prisons, schools, and sports authorities. To date, over 80 different drugs and compounds have been detected across 25 different categories of substances using this method. www.sensabues.com
About RCU Labs, Inc.
RCU Labs, Inc., was founded by an established team of eminent scientists, with an extensive background in clinical pharmacology, toxicology and molecular medicine, with the aim of developing new testing approaches to address a number of currently pressing problems facing law enforcement, governing bodies, employers and employees worldwide. RCU Labs, headquartered in Roseville, CA, is accredited to the ISO/IEC 17025 international standard in chemical and forensic testing. The company currently has four patents pending that support the underlying technology behind the RCU Test. www.rculabs.com
Humlegårdsgatan 4,114 46,
+44 (0) 781 808 7755